In conclusion, our data demonstrate that in Ang II-dependent hypertension, SGLT2 inhibitors have positive effects in counteracting the development of myocardial hypertrophy and fibrosis through mechanisms independent of their effect on glycemia. This evidence concerns the gene SLC5A2 and cardiac hypertrophy.